

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Thim et al.

Serial No.: TBA

Group Art Unit: TBA

Filed: March 20, 2000

Examiner: TBA

For: Human Spasmolytic Polypeptide in Glycosylated Form



**REQUEST TRANSFER OF COMPUTER READABLE
SEQUENCE LISTING FROM PARENT CASE**

Assistant Commissioner for Patents
Washington, DC 20231


Sir:

The computer-readable form in this application, Serial no. TBA is identical with that filed in Application Serial Nos. 08/491,976 and 09/027,893 filed August 2, 1995 and February 23, 1998. In accordance with 37 CFR 1.821(e), please use the only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing was separately filed with the Amendment and Response to Notice to File Missing Parts and to Notice to Comply with Sequence Rules filed on September 17, 1996 for incorporation into the specification.

The Examiner is hereby to contact the undersigned if there are any questions concerning this response.

Respectfully submitted,

Date: March 20, 2000



Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123